Pharma channel feed

As­traZeneca ex­pands chron­ic kid­ney dis­ease 'Tar­get' cam­paign for Farx­i­ga

3 years ago
Marketing

Fed­er­al judge up­holds Cabome­tyx patent in Ex­elix­is' gener­ic bat­tle

3 years ago
Law

Mar­tin Shkre­li is back in the crosshairs of the fed­er­al gov­ern­ment for not stay­ing out of phar­ma

3 years ago
Law

Ipsen's pan­cre­at­ic can­cer drug bests decade-old stan­dard of care

3 years ago
R&D

BeiGene's Brukin­sa wins CLL ap­proval af­ter top­ping Im­bru­vi­ca in head-to-head tri­al

3 years ago
China
FDA+

FDA squash­es ac­cel­er­at­ed hopes for Eli Lil­ly’s Alzheimer’s drug as agency asks for more da­ta

3 years ago
R&D
FDA+

Urovant taps celebri­ty ad­vo­cate and pa­tient Hol­ly Robin­son Peete for over­ac­tive blad­der ed­u­ca­tion

3 years ago
Marketing

New clin­i­cal tri­al sys­tem to soon be­come manda­to­ry in Eu­rope

3 years ago
FDA+

In­tas Phar­ma­ceu­ti­cals un­der FDA scruti­ny over 'cas­cade of fail­ure' in over­sight of GMP doc­u­ments

3 years ago
Manufacturing

Genen­tech touts pos­i­tive Phase III da­ta for Tecen­triq/Avastin com­bo in liv­er can­cer

3 years ago
R&D

By sum­mer sol­stice, we'll know the fate of In­ter­cep­t's NASH drug

3 years ago
FDA+

Mer­ck dis­cov­ers 'root cause' of ni­trosamine lev­els in block­buster di­a­betes drugs

3 years ago

Sun Phar­ma picks 'Dr. Pim­ple Pop­per' for ed­u­ca­tion­al ac­ne cam­paign

3 years ago
Marketing

Am­gen tar­gets physi­cians with biosim­i­lars ed­u­ca­tion cam­paign in ad­vance of ex­pect­ed 2023 break­out

3 years ago
Marketing

Up­dat­ed: FDA slaps Op­tum In­fu­sion with a warn­ing let­ter over 'in­san­i­tary' pro­duc­tion con­di­tions

3 years ago
Manufacturing

Bris­tol My­ers de­buts first Op­du­alag cam­paign, adds to its two-com­bo can­cer drug mar­ket­ing

3 years ago
Marketing

Am­gen ex­tends au­toim­mune pact with small Michi­gan biotech

3 years ago
Startups
Deals

J&J re­ports sec­ond HIV vac­cine reg­i­men fail­ure in 18 months

3 years ago
R&D

Ak­ili cuts about 30% of staff in ef­fort to be 'ex­treme­ly lean'

3 years ago
People

ICER: Ma­jor­i­ty of pay­er cov­er­age poli­cies sup­port 'key el­e­ments of fair ac­cess' in for­mu­la­ries

3 years ago

CMS ini­ti­ates cov­er­age analy­sis for provider-ad­min­is­tered PrEP to pre­vent HIV

3 years ago

PwC pre­dicts 'flur­ry' of $5B to $15B biotech deals in 2023

3 years ago
Deals

Drug name re­view: Sci­ence takes the spot­light in 2022

3 years ago
Marketing

Pfiz­er shifts full port­fo­lio to non-prof­it mod­el in 45 low­er-in­come coun­tries

3 years ago
First page Previous page 149150151152153154155 Next page Last page
A service from the Financial Times